Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) reported Q1 2026 results and program updates on May 5, 2026. Key items: FDA Breakthrough Therapy designation for zovegalisib in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer; 11.1‑month median PFS in CDK4/6‑experienced patients; Phase 3 ReDiscover‑2 ongoing; selected zovegalisib+atirmociclib triplet for 1L with Phase 3 planned in early 2027.
Cash, cash equivalents and investments were $642.1M at March 31, 2026; Q1 revenue was $3.0M; net loss was $73.3M ($0.41/share).
Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close. The company is a clinical-stage small molecule precision medicine firm focused on oncology and genetic-disease therapies.
Relay Therapeutics (Nasdaq: RLAY)/b) reported clinical data supporting advancement of into a planned Phase 3 frontline trial for PIK3CA‑mutated, HR+/HER2‑ metastatic breast cancer, targeting initiation in early 2027 pending regulatory feedback.
Key data: 44% ORR (15/34 measurable patients) in median third‑line, 3% zovegalisib discontinuation, 40% grade 3+ TRAE rate, and a pharmacokinetic interaction increasing zovegalisib exposure ~2.5‑fold. Pfizer will supply atirmociclib for the trial.
Relay Therapeutics (Nasdaq: RLAY) will present initial clinical and preclinical data for zovegalisib (RLY-2608) in vascular anomalies at the ISSVA World Congress 2026 in Philadelphia, May 19-22, 2026.
The company expects to report clinical data on approximately 20 efficacy-evaluable patients in a Late Breaking Abstract on May 20, 2026, and will present preclinical murine-model results showing lesion regression with minimal hyperinsulinemia on May 22, 2026. Presentations will be posted on the company website at session start times.
Relay Therapeutics (Nasdaq: RLAY) reported Phase 1/2 ReDiscover data for zovegalisib 400mg BID fed plus fulvestrant in PI3Kα‑mutated, HR+/HER2‑ metastatic breast cancer. Among 57 efficacy‑evaluable patients (data cut‑off Jan 13, 2026) median PFS was 11.1 months (95% CI: 7.3–13.0); ORR was 43% in 35 measurable patients. Pharmacokinetics showed 400mg fed exposures comparable to 600mg fasted. Safety was mainly low‑grade TRAEs; four discontinuations. Zovegalisib has FDA Breakthrough Therapy designation and the Phase 3 ReDiscover‑2 trial is ongoing.
Relay Therapeutics (Nasdaq: RLAY) reported Q4 and full-year 2025 results and outlined 2026 clinical milestones for zovegalisib. Key financials: $554.5M cash and investments at 12/31/25, $15.4M 2025 revenue, and $276.5M net loss for 2025. Clinical highlights include FDA Breakthrough Therapy designation, ESMO TAT presentation on March 16, 2026, and planned 1H 2026 data in PIK3CA-driven vascular anomalies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two investor fireside chats in March 2026. Management will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 10:30 a.m. ET.
Both sessions will be webcast live and archived replays will be available for up to 30 days via the company's Events page.
Relay Therapeutics (Nasdaq: RLAY) will report its fourth quarter and full year 2025 financial results and corporate highlights after U.S. market close on February 26, 2026. The company is a clinical-stage small molecule precision medicine firm focused on cancer and genetic disease therapies.
Relay Therapeutics (Nasdaq: RLAY) announced management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The session will be webcast live and an archived replay will be available for up to 30 days.
Investors can access the live and archived webcast via Relay Therapeutics’ Events page on its investor website.
Relay Therapeutics (Nasdaq: RLAY) announced the U.S. FDA granted Breakthrough Therapy designation to zovegalisib (RLY-2608) plus fulvestrant for adults with PIK3CA-mutant, HR+/HER2- locally advanced or metastatic breast cancer after progression on a CDK4/6 inhibitor.
BTD was supported by Phase 1/2 ReDiscover data including two comparable-dose cohorts: 600mg BID fasted (N=52) and 400mg BID fed (N=57), with 400mg BID as the Phase 3 dose; 400mg fed data will be presented March 16, 2026.